Search
Now showing items 21-21 of 21
Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina
(Elsevier, 2020-09)
Abstract
Background: Nivolumab was the first anti-programmed cell death 1 drug approved in Argentina for non-small-cell lung cancer treatment in the second-line setting.
Materials and methods: The present study was a ...